USA Archives

News and Trends 20 Oct 2022

Partnership formed to make drug for MoCD Type A available sooner

Inceptua Early Access and Sentynl Therapeutics Inc., a U.S.-based biopharmaceutical company bringing therapies to patients living with rare diseases, have entered into a partnership. The partnership is to make Sentynl’s Nulibry available via an early access program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A. MoCD Type A is a rapidly progressive autosomal […]

October 20, 2022 - 2 minutesmins - By Liza Laws

brain cancer glioblastoma divide and conquer

News and Trends 20 Oct 2022

Healthy volunteer study for tablet to treat brain cancer open for recruitment

A clinical stage drug company developing sulforaphane-based medicines for cancer treatment has started recruiting for a pharmacokinetic / pharmacodynamic trial in healthy volunteers (HV). Evgen Pharma plc also announced the start an investigator sponsored clinical study (ISS) for a glioblastoma program. The purpose of the HV study is to examine the performance of Evgen’s new […]

October 20, 2022 - 4 minutesmins - By Liza Laws

News and Trends 19 Oct 2022

Multi-year agreement to boost women’s reproductive health

A multi-year agreement between BioSkryb Genomics and Cooper Genomics, a reproductive health company was announced yesterday (October 18). The agreement is to license BioSkyrb’s proprietary genomic amplification technology. Cooper will utilize the Bioskryb technology to enhance their preimplantation genetic testing (PGT) capabilities. The agreement will also allow Cooper to boost BioSkyrb’s tech for the PGT […]

October 19, 2022 - 3 minutesmins - By Liza Laws

News and Trends 19 Oct 2022

Report says 20% of global cancer deaths could be avoided

A new study by members of the Bloomberg New Economy International Cancer Coalition says at least 1.5 million deaths from cancer could be avoided each year. This is 20% of the annual global deaths resulting from cancer. The study says this could happen if international regulations around patient trials were more standardized and people placed […]

October 19, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

Empyrean Neuroscience launches with $22M to target CNS disorders

Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company, based in New York City and Cambridge, U.K., is founded on a proprietary platform designed to genetically engineer small molecule therapeutics […]

October 18, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

Progress of COPD drug boosted by debt financing of up to $150M

Verona Pharma plc has today (October 17) announced that it has entered into a debt financing facility providing access of up to $150 million from Oxford Finance LLC. The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine, the company’s product candidate, which recently reported positive phase 3 data in the […]

October 18, 2022 - 2 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

Gene activity could help identify risk of kidney cancer spreading

Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumor spreading and the patient’s chances of survival. This is shown by researchers from Karolinska Institutet (KI) in Sweden in a preclinical study published in Nature Communications. “This could potentially […]

October 17, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

More positive news announced for Verona’s COPD treatment

Clinical-stage biopharmaceutical company, Verona, has announced more positive news from its phase 3 ENHANCE-2 clinical trial of ensifentrine that treats chronic obstructive pulmonary disease (COPD). The company focuses on respiratory diseases, and made the announcement today (October 14) about the positive analyses demonstrating how ensifentrine reduced exacerbation rates across subgroups in the trial. Ensifentrine is […]

October 17, 2022 - 3 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

Way to transform Cas-9 protein into spherical nuclear acid developed

A team of researchers at U.S. Northwestern University has developed a way to transform the Cas-9 protein into a spherical nuclear acid (SNA). It can then be loaded with critical components as required to access a broad range of tissue and cell types, as well as the intracellular compartments required for gene editing. The team […]

October 17, 2022 - 4 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

PerkinElmer’s Horizon Discovery: the lowdown on base editing

PerkinElmer’s Horizon Discovery provides cell engineering tools and services for researchers in drug discovery and development. Horizon’s portfolio is focused on research reagents; screening and cell line engineering services; bioproduction cell lines; reference standards and base editing. Horizon’s base editing platform, Pin-point is a gene editing method with the ability to effect multiple single base edits […]

October 17, 2022 - 5 minutesmins - By Jim Cornall

More News! 14 Oct 2022

ChristianaCare spins out new gene-editing company CorriXR Therapeutics

ChristianaCare has spun out its first commercial biotech private start-up company, CorriXR Therapeutics. CorriXR Therapeutics will use CRISPR gene editing technology to develop new, clinically relevant oncologic therapeutics in areas of unmet medical need, starting with squamous cell carcinoma of the lung. Its close relationship with ChristianaCare and the ChristianaCare Gene Editing Institute positions it […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Oct 2022

Cytel signs agreement with two Scandinavian medicinal product companies

U.S.-based Cytel Inc. has entered into an agreement to acquire Scandinavian companies SDS Life Sciences AB and SDS MedeQ AB. Cytel says the move will add new talent to the company’s strategic consulting group and bring additional capabilities for the development of drugs and medical devices. It says sponsors will also have easier access to […]

October 14, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Partnership formed to make drug for MoCD Type A available sooner

Healthy volunteer study for tablet to treat brain cancer open for recruitment

Multi-year agreement to boost women’s reproductive health

Report says 20% of global cancer deaths could be avoided

Empyrean Neuroscience launches with $22M to target CNS disorders

Progress of COPD drug boosted by debt financing of up to $150M

Gene activity could help identify risk of kidney cancer spreading

More positive news announced for Verona’s COPD treatment

Way to transform Cas-9 protein into spherical nuclear acid developed

PerkinElmer’s Horizon Discovery: the lowdown on base editing

ChristianaCare spins out new gene-editing company CorriXR Therapeutics

Cytel signs agreement with two Scandinavian medicinal product companies

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!